RA reports grants for research support (related to treatment of ulcerative colitis broadly) from InDex Pharmaceuticals; consulting fees (related to treatment of ulcerative colitis broadly) from InDex Pharmaceuticals; honoraria for lectures (all related to treatment of ulcerative colitis broadly) from AbbVie, Amgen, Arena Pharmaceuticals (related to etrasimod), Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Falk Foundation, Fresenius Kabi, Galapagos, InDex Pharmaceuticals, Janssen-Cilag, Lilly, MSD, Roche Pharma, Samsung Bioepsis, and Takeda Pharma; support for attending meetings and travel from Janssen-Cilag; and advisory board fees (all related to treatment of ulcerative colitis broadly) from AbbVie, Arena Pharmaceuticals (related to etrasimod), Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion Healthcare, Galapagos, Gilead, InDex Pharmaceuticals, Janssen-Cilag, Kliniksa Pharmaceuticals, Lilly, Pandion Therapeutics, Roche Pharma, Samsung Bioepsis, Takeda Pharma, and Viatris. MFN reports consulting fees (related to treatment of ulcerative colitis broadly) from AbbVie, MSD, Takeda, Boehringer, Roche, Pfizer, Janssen, PPD, and Pentax.